Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Inclusion Criteria: * Histologically or cytologically confirmed advanced solid malignancy * Patients enrolled in stratum II of the study must have BRCA1/2 mutation (added 04/07/09) * Patients with CNS metastases must be stable after therapy for CNS metastases (such as surgery, radiotherapy or stereotactic radiosurgery) for \> 3 months and must be off steroid treatment prior to study enrollment * ECOG performance status 0-2 * Life expectancy \> 12 weeks * ANC ≥ 1,500/μL * Platelet count ≥ 100,000/μL * Total bilirubin ≤ 1.5 times upper limit of normal (ULN) * AST and ALT ≤ 2.5 times ULN * Creatinine normal OR creatinine clearance ≥ 60 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment * More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) * More than 3 weeks since prior radiotherapy * Prior veliparib allowed Exclusion Criteria: * Known history of allergic reactions to veliparib, carboplatin, or Cremophor-paclitaxel * Uncontrolled intercurrent illness, including, but not limited to, any of the following: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Psychiatric illness or social situations that would preclude compliance with study requirements * Peripheral neuropathy \> grade 1 * Inability to take oral medications on a continuous basis * Active…